At first glance, uveal melanoma and cutaneous melanoma appear closely related. Both arise from melanocytes, both can become metastatic, and both carry significant implications for patients and care teams. Yet in oncology, similarities can sometimes be misleading. Metastatic uveal melanoma (mUM) is a distinct disease with unique biology, clinical behavior, and treatment considerations. However, patients with mUM historically have been managed using treatment approaches developed for cutaneous melanoma despite important differences in genetics, patterns of metastasis, and therapeutic response. Our team at The France Foundation (TFF) partnered with the Association of VA Hematology/Oncology (AVAHO) to break down barriers to optimal care by developing Addressing Unmet Needs in Metastatic Uveal Melanoma, an educational initiative that helps clinicians recognize the unique characteristics of this disease. 

Two Diseases With Different Paths

mUM should not be viewed simply as a subtype of cutaneous melanoma. These diseases differ significantly in incidence, molecular drivers, and metastatic behavior. Their biological differences have important clinical consequences; and many therapies that transformed outcomes in cutaneous melanoma have demonstrated limited efficacy in mUM, which makes disease-specific treatment strategies essential.  

For patients with mUM, HLA-A*02:01 testing has emerged as a critical component of clinical decision making, helping to identify patients who may be eligible for novel T-cell receptor (TCR)-based therapies and influencing treatment selection. Despite this, awareness and utilization of HLA testing are inconsistent, and many clinicians are unfamiliar with the distinctions between the two diseases and their implications for patient care. Uncertainty around when to order testing, how to interpret results, and how HLA status affects treatment eligibility creates delays to accessing potentially beneficial therapies, and Addressing Unmet Needs in Metastatic Uveal Melanoma was designed to provide answers. 

Our program focuses on the emergence of bispecific T-cell receptor therapies, which has introduced an entirely new approach to treating mUM. Unlike immune checkpoint inhibitors, which enhance existing immune responses, TCR-based therapies actively redirect T cells toward tumor cells through highly specific interactions between tumor-associated antigens and HLA-presented peptides. This mechanism represents a significant shift in how clinicians think about immunotherapy and patient selection, but these therapies also introduce an entirely new clinical vocabulary for clinicians, from HLA restriction and peptide presentation to treatment eligibility and toxicity management. As such, we designed the program to explain not only what these therapies do, but why they work. 

Translating Evidence Into Present and Future Care

One of the greatest challenges this program was developed to address is the uncertainty that many clinicians experience when interpreting clinical trial data related to bispecific TCR therapies. Understanding efficacy endpoints, safety considerations, patient selection criteria, and real-world applicability requires more than simply reviewing published results. Addressing Unmet Needs in Metastatic Uveal Melanoma helps clinicians bridge that gap by providing practical, expert-led discussions on clinical trial findings, treatment pathways, and patient management considerations within both academic and VA settings. 

Our goal is not only to improve knowledge but to strengthen confidence and support evidence-based decision making, and the response to this initiative underscores a broader trend in health care education. Participation has already exceeded expectations, revealing significant demand for education focused on rare cancers and emerging treatment approaches. While the program isn’t over yet, the lessons we’ve learned are clear: clinicians are actively seeking guidance on how to navigate rapidly evolving therapeutic landscapes, particularly in disease states where traditional treatment paradigms are being redefined. 

As the treatment landscape for mUM continues to evolve, with multiple investigational approaches currently being studied—including additional TCR-based therapies, targeted therapies, and combination treatment strategies—we strive to ensure that education evolves alongside it. Programs like Addressing Unmet Needs in Metastatic Uveal Melanoma that help health care professionals understand emerging science, implement precision testing strategies, and translate complex evidence into patient-centered care will play an increasingly important role in improving outcomes for patients with rare and challenging diseases. 

"The true value of this program is that it turns a rapidly changing and highly specialized field into actionable knowledge clinicians can use to improve patient care," says Dr. Marlana Orloff, Professor of Medical Oncology, Alexander & Johnston Family Endowed Clinical Director of Uveal Melanoma, and Co-Director for the Melanoma Research Institute of Excellence at Thomas Jefferson University Hospital. "Though uveal melanoma is fortunately a rare cancer, we are often looking for ways to better educate other clinicians; and this program with The France Foundation did just that."

In mUM’s case, recognizing the difference between what appears familiar and what is fundamentally distinct may be one of the most important steps toward advancing care. 

Breakthrough therapies are only as impactful as the clinicians prepared to use them. Our team at The France Foundation works to help health care professionals navigate emerging science, adopt innovative treatment strategies, and improve patient care. From precision medicine to rare disease management, our initiatives are designed to translate complex evidence into meaningful clinical action. We welcome opportunities to collaborate with organizations seeking to accelerate understanding and implementation of advances in oncology and beyond. Get in touch with us using the form below.